pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 11·1 min read
save

Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push

Daiichi Sankyo is betting on its oncology franchise to push it past 3 trillion Japanese yen ($19 billion) in 2030 revenues. The drugmaker published a new five-year business plan on Monday ...

May 11, 2026·read at Endpoints ↗

May 11, 2026 11:35 AM EDT R&DPharma Dai­ichi eyes al­most $15B in on­col­o­gy sales by 2030 in ADC fran­chise push Ayisha Sharma News Reporter Dai­ichi Sankyo is bet­ting on its on­col­o­gy fran­chise to push it past 3 tril­lion Japan­ese yen ($19 bil­lion) in 2030 rev­enues. The drug­mak­er pub­lished a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
84 words · retrieved May 11
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
DAIICHI SANKYO
topics
Antibody-Drug Conjugate (ADC)2Oncology2

related stories

  • Aug 6Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027Fierce Biotech
  • Aug 3‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal everBioSpace
  • Jul 30Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsBioSpace
  • Jul 29Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combinationFierce Biotech
  • Jul 28GSK partner Hansoh reports another phase 3 win for priority ADCFierce Biotech